检索结果-南通市图书馆

World Journal of Gastrointestinal Oncology 2025年第1期17卷 226-232页

作者： Kai Chen Xu Feng Yuan Shi Xin-Lin Li Zheng-Rong Shi Xiang Lan Department of Hepatobiliary Surgery The First Affiliated Hospital of Chongqing Medical UniversityChongqing 400016China

BACKGROUND Gallbladder cancer(GBC)is the most common and aggressive subtype of biliary tract cancer(BTC)and has a poor prognosis.A newly developed regimen of gemcitabine,cisplatin,and durvalumab shows promise for the treatment of advanced ***,the efficacy of this treatment for GBC remains *** SUMMARY In this report,we present a case in which the triple-drug regimen exhibited marked effectiveness in treating locally advanced GBC,thus leading to a long-term survival benefit.A 68-year-old man was diagnosed with locally advanced GBC,which rendered him ineligible for curative *** three cycles of therapy,a partial response was *** one year of combined therapy,a clinical complete response was successfully *** maintenance therapy with durvalumab monotherapy resulted in a disease-free survival of 9 months for the *** patient experienced tolerable toxicities of reversible grade 2 nausea and *** adverse events were observed in the patient throughout the entirety of the *** The combination of gemcitabine and cisplatin chemotherapy with durvalumab was proven to be an effective treatment approach for advanced GBC,with manageable adverse *** research is warranted to substantiate the effectiveness of the combined regimen in the context of GBC.

关键词： Gallbladder cancer Chemotherapy Immunotherapy durvalumab Complete response Case report

治疗尿路上皮癌新药——程序性死亡配体1抑制剂durvalumab

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中国新药与临床杂志 2018年第7期37卷 391-394页

作者：汪龙宋佳伟韩一萱张莉蚌埠市第三人民医院药学部安徽蚌埠233099 亳州市人民医院药学部安徽亳州236800 蚌埠医学院第二附属医院药学部安徽蚌埠233040

durvalumab是由阿斯利康公司研发的完全人源化的抑制程序性死亡配体1(PD-L1)的Ig G1单克隆抗体。2017年5月1日,美国食品和药物管理局批准durvalumab用于局部晚期或转移性尿路上皮癌患者的治疗。本文主要介绍其药物作用机制、药动学、临... 详细信息

durvalumab是由阿斯利康公司研发的完全人源化的抑制程序性死亡配体1(PD-L1)的Ig G1单克隆抗体。2017年5月1日,美国食品和药物管理局批准durvalumab用于局部晚期或转移性尿路上皮癌患者的治疗。本文主要介绍其药物作用机制、药动学、临床研究及安全性。

关键词： durvalumab 尿路上皮癌药理作用药动学临床研究不良反应

CASPIAN研究:durvalumab联合化疗为广泛期小细胞肺癌患者带来总生存期获益

在线全文

学校读者我要写书评

暂无评论

循证医学 2020年第3期20卷 158-162页

作者：吴雨微(评价) 赵明芳(评价) 柯娥娥中国医科大学附属第一医院肿瘤内科二病房沈阳110001 中国医科大学附属第一医院肿瘤内科沈阳110001 广东省人民医院肿瘤中心、广东省医学科学院、广东省肺癌研究所广州510080

1文献来源Paz-Ares L,Dvorkin M,Chen Y,et *** plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer(CASPIAN):A randomised,controlled,open-label,phase 3 trial[J].Lancet,2019,394(10212):1929-1939.2证据水平1b。3背景在过去的30年中,广泛期小细胞肺癌(extensive-stage small-cell lung cancer,ES-SCLC)公认的一线标准治疗方案为依托泊苷联合卡铂或顺铂(platinum-etoposide,EP)化疗。但大多数患者在接受治疗的6个月内复发,中位总生存期(overall survival,OS)仅为10个月左右。

关键词：广泛期小细胞肺癌 durvalumab PD-1/PD-L1抑制剂一线治疗

durvalumab治疗放化疗后Ⅲ期非小细胞肺癌患者的总生存期获益

在线全文

学校读者我要写书评

暂无评论

循证医学 2020年第1期20卷 49-52页

作者：蒋苏静谢聪颖卢红莲温州医科大学附属第一医院放化疗科浙江温州325000 广东省人民医院肿瘤中心广东省医学科学院广东省肺癌研究所华南理工大学医学院广州510080

1文献来源Antonia SJ,Villegas A,Daniel D,et *** survival with durvalumab after chemoradiotherapy in stageⅢNSCLC[J].N Engl J Med,2018,379(24):2342-2350.2证据水平1b。3背景durvalumab是一种选择性、高亲和力的人源IgG1单克隆抗体,能阻断程序性死亡-配体1(programmed death-ligand 1,PD-L1)与程序性死亡受体-1(programmed death-1,PD-1)和CD80的结合,使T细胞识别和杀伤肿瘤细胞。

关键词：非小细胞肺癌总生存期 durvalumab

FDA批准抗肿瘤药durvalumab上市

在线全文

学校读者我要写书评

暂无评论

中国执业药师 2017年第6期14卷 75-75页

美国FDA于2017年5月1日批准阿斯利康(Astrazeneca)公司的durvalumab(商品名:Imfinzi)注射液上市,用于局部晚期或转移性尿路上皮癌。程序性死亡蛋白配体-1(PD-L1)的表达可由炎症信号(如IFN-γ)诱导,在肿瘤微环境中可在肿瘤细胞和肿瘤相... 详细信息

美国FDA于2017年5月1日批准阿斯利康(Astrazeneca)公司的durvalumab(商品名:Imfinzi)注射液上市,用于局部晚期或转移性尿路上皮癌。程序性死亡蛋白配体-1(PD-L1)的表达可由炎症信号(如IFN-γ)诱导,在肿瘤微环境中可在肿瘤细胞和肿瘤相关免疫细胞上表达。PD-L1通过与程序性死亡蛋白(PD)-1和CD80(B7.1)相互作用阻断T细胞功能和T细胞激活,通过与其受体结合,可减少细胞毒性T细胞活性、T细胞增殖和细胞因子产生。

关键词： FDA durvalumab 死亡蛋白

Programmed cell death-1 inhibitor-related sclerosing cholangitis:A systematic review

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2020年第3期26卷 353-365页

作者： Takumi Onoyama Yohei Takeda Taro Yamashita Wataru Hamamoto Yuri Sakamoto Hiroki Koda Soichiro Kawata Kazuya Matsumoto Hajime Isomoto Division of Medicine and Clinical Science Department of Multidisciplinary Internal MedicineFaculty of MedicineTottori UniversityTottori prefecture 683-8504Japan Internal Medicine Irisawa Medical ClinicShimane prefecture 690-0025Japan

BACKGROUND Programmed cell death-1(PD-1)inhibitor has been indicated for many types of ***,these inhibitors also cause immune-related adverse *** disorder is a phenotype of immune-related adverse event affecting 0%–4.5%of patients treated with PD-1 *** studies have reported PD-1 inhibitor-related sclerosing cholangitis(SC);however,the associated clinical and pathological features are *** To evaluate the clinical and pathological features of PD-1 inhibitor-related SC through a systematic review of the *** The review,conducted using electronic databases in PubMed,was restricted to the period from January 2014 to September 2019 and focused on case reports/series on PD-1 inhibitor-related SC published in *** scanned the references of the selected literature to identify any further relevant *** cases previously studied by us,including three that have not yet been published,were included in this *** Thirty-one PD-1 inhibitor-related SC cases were *** age of patients was 67 years(range,43–89),with a male to female ratio of 21:*** main disease requiring PD-1 inhibitor treatment was non-small cell lung *** that caused PD-1 inhibitor-related SC were nivolumab(19 cases),pembrolizumab(10 cases),avelumab(1 case),and durvalumab(1 case).The median number of cycles until PD-1 inhibitor-related SC onset was 5.5(range,1–27).Abdominal pain or discomfort(35.5%,11/31)was the most frequent *** serum tests identified liver dysfunction with a notable increase in biliary tract enzymes relative to hepatic enzymes,and a normal level of serum immunoglobulin *** dilation without obstruction(76.9%,20/26),diffuse hypertrophy of the extrahepatic biliary tract(90.5%,19/21),and multiple strictures of the intrahepatic biliary tract(30.4%,7/23)were *** 11/23(47.8%)cases,pathological examination indicated that CD8+T cells were the dominant inflammatory cells i

关键词： Nivolumab Pembrolizumab Avelumab durvalumab Atezolizumab Programmed cell death-1 inhibitor Immune-related adverse events Cholangitis

The tumor microenvironment of pancreatic adenocarcinoma and immune checkpoint inhibitor resistance: a perplex relationship

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Drug Resistance 2020年第4期3卷 699-709页

作者： Irem Sahin Sevda Turen Pranav Santapuram Ibrahim Halil Sahin Baskent University School of Medicine Department of Medicine AnkaraAnkara 06810Turkey TC Istanbul Kültür University Faculty of Health SciencesDepartment of NursingIstanbul 34158Turkey Emory University School of Medicine Department of MedicineAtlantaGA 30322USA Moffitt Cancer Center Department of Gastrointestinal OncologyTampaFL 33612USA

Pancreatic cancer is one of the most aggressive cancers with a high mortality rate even among patients with early-stage *** recent studies with novel therapeutic approaches have led to modest improvement in survival outcomes,limited progress is achieved for the use of immunotherapeutics in this challenging *** checkpoint inhibitors,thus far,single-agent or in combination,have not yielded significant improvement in survival outcomes except in mismatch repair-deficient pancreatic *** tumor microenvironment of pancreatic cancer has been considered as an attractive target for over a decade based on preclinical studies that suggested it may adversely affect drug delivery and antitumor *** this review article,we elaborate on the biology of pancreatic cancer microenvironment,its highly complicated interaction with cancer cells,and the immune *** also discuss plausible explanations that led to the failure of immune checkpoint inhibitors as therapeutic agents and the potential impacts of pancreatic cancer stroma on these negative studies.

关键词： Pancreatic adenocarcinoma durvalumab nivolumab ipilimumab pembrolizumab immune checkpoint inhibitors immunotherapy resistance mismatch repair deficient microsatellite instability high microsatellite stable tumor-associated macrophages myeloid-derived suppressor cells T regs T cells

Duravlumab在中国Ⅲ期非小细胞肺癌放化疗后巩固治疗中的成本效果分析

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中国医学工程 2021年第3期29卷 7-11页

作者：姚林利佘龙江丁冬祝友文石茵黄进中南大学湘雅医院肿瘤科湖南长沙410008 中南大学湘雅医院药学部湖南长沙410008

目的该研究的目的主要是估算durvalumab在Ⅲ期非小细胞肺癌(NSCLC)同步放化疗以后巩固治疗中中国地区的成本效果性。方法基于大型Ⅲ期临床试验PACIFIC的数据构建马尔可夫模型。每组的成本生命年(LYs),质量调整生命年(QALYs)及增量成本... 详细信息

目的该研究的目的主要是估算durvalumab在Ⅲ期非小细胞肺癌(NSCLC)同步放化疗以后巩固治疗中中国地区的成本效果性。方法基于大型Ⅲ期临床试验PACIFIC的数据构建马尔可夫模型。每组的成本生命年(LYs),质量调整生命年(QALYs)及增量成本效果比(ICERs)将会得到估算。使用一元敏感度及概率敏感度分析进行模型稳定性评估。结果durvalumab巩固治疗组对比安慰剂组分别产生了2.91QALYs和2.39QALYs,总费用分别是$58636和$47349,因此对比安慰剂组,durvalumab的ICER是$22067/QALY。结论当意愿支付值(WTP)为$30828时,在中国,不可切除的Ⅲ期非小细胞肺癌同步放化疗以后,durvalumab巩固治疗似乎是一个具有成本效果性的选择。

关键词： durvalumab Ⅲ期非小细胞肺癌巩固治疗成本效果性

Deep diving in the PACIFIC:Practical issues in stage III non-small cell lung cancer to avoid shipwreck

在线全文

学校读者我要写书评

暂无评论

World Journal of Clinical Oncology 2020年第11期11卷 898-917,I0003页

作者： Xabier Mielgo-Rubio Federico Rojo Laura Mezquita-Pérez Francesc Casas Amadeo Wals Manel Juan Carlos Aguado Javier Garde-Noguera David Vicente Felipe Couñago Department of Medical Oncology Hospital Universitario Fundación AlcorcónMadrid 28922Spain Department of Pathology IIS-Jiménez Díaz-CIBERONC FoundationMadrid 28040Spain Department of Medical Oncology Hospital ClinicLaboratory of Translational Genomics and Targeted Therapeutics in Solid TumorsIDIBAPSBarcelona 08036Spain Department of Radiation Oncology Hospital ClinicBarcelona 08036Spain Department of Radiation Oncology Hospital Universitario Virgen MacarenaSevilla 41009Spain Department of Immunology Service Hospital ClínicUniversitat de BarcelonaBarcelona 08036Spain Department of Medical Oncology Hospital Universitario Clínico San CarlosMadrid 28040Spain Department of Medical Oncology Hospital Universitario Virgen MacarenaSevilla 49001Spain Department of Radiation Oncology Hospital Universitario Quirónsalud MadridHospital La LuzUniversidad Europea de MadridMadrid 28028Spain

After publication of the PACIFIC trial results,immune checkpoint inhibitor-based immunotherapy was included in the treatment algorithm of locally advanced non-small cell lung cancer(NSCLC).The PACIFIC trial demonstrated that 12 mo of durvalumab consolidation therapy after radical-intent platinum doublet chemotherapy with concomitant radiotherapy improved both progression-free survival and overall survival in patients with unresectable stage III *** is the first treatment in decades to successfully improve survival in this clinical setting,with manageable toxicity and without deterioration in quality of *** integration of durvalumab in the management of locally advanced NSCLC accentuates the need for multidisciplinary,coordinated decision-making among lung cancer specialists,bringing new challenges and controversies as well as important changes in clinical work *** aim of the present article is to review—from a practical,multidisciplinary perspective—the findings and implications of the PACIFIC *** evaluate the immunobiological basis of durvalumab as well as practical aspects related to programmed cell death ligand 1 *** addition,we comprehensively assess the efficacy and toxicity data from the PACIFIC trial and discuss the controversies and practical aspects of incorporating durvalumab into routine clinical ***,we discuss unresolved questions and future *** short,the present document aims to provide clinicians with a practical guide for the application of the PACIFIC regimen in routine clinical practice.

关键词： durvalumab Non-small cell lung cancer PACIFIC Immunotherapy Immune checkpoint inhibitors Anti-programmed cell death ligand 1 Consolidation therapy Unresectable stage III lung cancer

New perspectives in the management of small cell lung cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Clinical Oncology 2022年第6期13卷 429-447页

作者： Cristina Pangua Jacobo Rogado Gloria Serrano-Montero JoséBelda-Sanchís BeatrizÁlvarez Rodríguez Laura Torrado Nuria Rodríguez De Dios Xabier Mielgo-Rubio Juan Carlos Trujillo Felipe Couñago Department of Medical Oncology Hospital Universitario Infanta LeonorMadrid 28031Spain Department of Thoracic Surgery Hospital de la Santa Creu i Sant Pau&Hospital de MarUniversitat Autònoma de BarcelonaBarcelona 08041CataloniaSpain Department of Radiation Oncology Hospital Universitario HM SanchinarroHM HospitalesHM CIOCC Centro Integral Oncológico Clara CampalMadrid 28050Spain Department of Radiation Oncology Hospital Universitario Lucus Augusti&Instituto de Investigación Sanitaria Santiago de Compostela(IDIS)Lugo 27003Spain Department of Radiation Oncology Hospital Del Mar&Hospital Del Mar Medical Research Institute(IMIM)&Pompeu Fabra UniversityBarcelona 08003CataloniaSpain Department of Medical Oncology Alcorcón Foundation University HospitalAlcorcón 28922MadridSpain Department of Thoracic Surgery Hospital de la Santa Creu i Sant PauBarcelona 08029Spain Department of Radiation Oncology Hospital Universitario Quirónsalud MadridHospital La LuzUniversidad Europea de MadridMadrid 28223Spain

The treatment of small cell lung cancer(SCLC)is a challenge for all specialists *** treatments have been added to the therapeutic armamentarium in recent months,but efforts must continue to improve both survival and quality of *** in surgery and radiotherapy have resulted in prolonged survival times and fewer complications,while more careful patient selection has led to increased staging *** in the field of systemic therapy have resulted in changes to clinical guidelines and the management of patients with advanced disease,mainly with the introduction of *** this article,we describe recent improvements in the management of patients with SCLC,review current treatments,and discuss future lines of research.

关键词： Small cell lung cancer Whole-brain radiotherapy Prophylactic cranial irradiation Stereotactic body radiotherapy Immunotherapy Atezolizumab durvalumab